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Abstract
Background: Despite of a growing number of gemcitabine based chemoradiotherapy studies in locally advanced
pancreatic cancer (LAPC), 5-fluorouracil based regimens are still regarded to be standard and the debate of
superiority between the two drugs is going on. The aim of this retrospective analysis was to evaluate the effect of
two concurrent chemoradiotherapy regimens using 5-fluorouracil or gemcitabine to compare their effect and
tolerance.
Methods: We have performed a single centre retrospective analysis of 93 patients treated with conventionally
fractionated radiotherapy of 55.8 Gray using either concurrent 5-fluorouracil, 1 g/m² on days 1-5 and 29-33 of
radiotherapy and 10 mg/m² of mitomycin C on day 1, 29 of radiotherapy (FM group, 35 patients) versus
gemcitabine (300 mg/m²) and cisplatin, (30 mg/m²) on days 1, 8, 22, and 29 (GC group, 58 patients). Primary
endpoint was the median overall survival (OS) rate.
Results: The median OS rate was 12.7 months in the GC group and 9.7 months in the FM group. The 1-year OS
rate was 53% versus 40%, respectively (p = 0.009). GC led to more grade 3 leukocytopenia and thrombocytopenia
than FM, but not to more grade 4 myelosuppression. Thrombocytopenia was the most frequently observed grade
4 toxicity in both groups (11% after FM versus 12% after GC). No grade 3/4 febrile neutropenia was observed.
Grade 3 nausea was more common in the FM group (20% versus 9%) and grade 4 nausea was observed in one
patient per group only.
Conclusions: GC was superior to FM for overall survival and both regimens were similar in terms of tolerance. We
conclude that GC leads to encouraging results and that the use of FM for chemoradiotherapy in LAPC cannot be
recommended without concerns.
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Background
Pancreatic ductal adenocarcinoma (PDAC), commonly
known as pancreatic cancer, is the 10th most common
cancer type with an incidence of 10/100,000 but highly
lethal (> 95%) and this is reflected by the fact that it is
ranking as the 5th most lethal cancer in absolute patient
numbers after lung, colorectal, breast and prostate
cancer [1,2]. Due to the declines in lethality in other
major cancers, pancreatic cancer is predicted to become
the fourth cause of cancer death in Europe [2]. Dramatic
progress was made during the past years to better
understand the biology of this disease (reviewed in [3]).
Only 10-20% of the patients have resectable tumours at
diagnosis and resection is a prerequisite for cure but
even with adjuvant therapy median overall survival of
resected patients is still as low as 20% after 5 years in
randomised phase III studies (reviewed in [4]). The large
majority (> 80%) of patients with non-resectable disease
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at diagnosis can be subdivided into metastatic and
locally advanced PDAC (LAPC) with both stages being
about equally frequent. Compared with metastatic dis-
ease patients with LAPC have a better prognosis and -
though often grouped together with metastatic disease
not separated in randomised phase III trials - patients
with LAPC should be separated from patients with
metastatic disease.
Chemotherapy is an essential element in the treatment
of LAPC to fight the high tendency of distant spread.
But the combination of systemic with local treatment
prolonged survival in a number of recent studies [5,6]
compared with systemic therapy only. Of note, second-
ary resection after CRT was reported in a systematic
review and meta-analysis in 1/3 of the patients leading
to a median overall survival (mOS) rate of 20.5 months
which is equally good as after primary resection [7] and
downstaging was also described [8]. On the other hand,
the inferiority of chemoradiotherapy (CRT) vs che-
motherapy in a recent French trial [9] can most likely
be attributed to inadequate technique and quality of
chemoradiotherapy highlighting the complexities of
CRT for PDAC [10]. Of note, 60 Gy were delivered in 2
Gy fractions to both the primary tumour and the elec-
tive lymphatics resulting in large planning target
volumes (PTV) as 2 cm expansion margins were used
from the clinical target volumes. Also, the FFCD-SFRO
trial [9] is the only randomised phase III CRT trial
using 5-fluorouracil (5-FU)/Cisplatin as concurrent che-
motherapeutic agents and this resulted in a very high
rate of grade 3/4 toxicity for the adjuvant chemotherapy
and prevented maintenance chemotherapy. Commonly,
the combination of a fluoropyrimidine with radiotherapy
is regarded to be the standard of care for CRT [4] but a
substantial number of gemcitabine based CRT trials was
reported with encouraging results such as in the ECOG-
4201 trial [6]. The latter trial used IMRT together with
600 mg/m2 gemcitabine weekly, a relatively high dose,
resulting in a high rate of grade 3/4 toxicity.
The rationale for preferring gemcitabine over 5-FU in
CRT regimens is its hypothesised superiority both,
locally and systemically: in metastatic disease gemcita-
bine was able to prolong survival and to lead to higher
clinical benefit compared to 5-FU [11]. For the local
effect when used with radiotherapy, gemcitabine is pre-
dicted to lead to higher tumour cytotoxicity than 5-FU
because it is one of the most potent radiosensitising
chemotherapeutic agents [12]. Gemcitabine is an S-
phase specific deoxycytidine analogue. It acts via compe-
titive incorporation of dFdCTP and dCTP into DNA
and results in DNA fragmentation and subsequent cell
death. Furthermore, gemcitabine interferes with ribonu-
cleotide reductase which is thought to have an impact
on cell death by affecting DNA repair. Also, specific
single-nucleotide polymorphisms in DNA the repair
damage genes ATM, Chek1 and ATR were found to be
significantly associated with OS after gemcitabine CRT
especially when analysed for the combined effect of all
three genes [13]. In line with these observations, gemci-
tabine containing schedules were described to achieve a
higher rate of pathologic response compared to 5-FU
based protocols [14]. The combination of gemcitabine
with 5-FU or capecitabine which is commonly used as a
chemotherapy combination was found to be too toxic
for CRT in LAPC especially in terms of elevated gastro-
intestinal toxicity [15]. Therefore we decided a different
chemotherapeutic combination, gemcitabine and cispla-
tin, which had been investigated both preclinically and
clinically: the synergism between the two drugs is attrib-
uted mainly to an increase in platinum-DNA adduct for-
mation which is possibly related to changes in DNA due
to dFdC incorporation into the DNA [16-18]. The com-
bination of the two drugs is clinically in use mainly in
ovarian, non-small cell lung and pancreatic cancer and
has been more effective than gemcitabine only in meta-
static and locally advanced PDAC in the group of
patients with good performance status [19].
Despite of this rationale, gemcitabine initially was dif-
ficult to be combined with radiotherapy due to its acute
toxicity profile depending profoundly on the absolute
radiotherapy treatment volume [18,20]. This potential
dangerous effect can now be more easily counter-
balanced with highly conformal treatment planning and
the use of IMRT/IGRT thereby increasing the tolerance
of gemcitabine based CRT [21]. In this analysis we com-
pare the outcome and the toxicity of two CRT regimens
in 93 patients with LAPC treated at our centre: One
regimen was 5-FU/Mitomycin C (FM), the other gemci-
tabine/cisplatin (GC) given concurrently with radiother-
apy. These two regimens have not been compared in
the literature up to now but they both have been used
in a number of trials in PDAC and other upper GI
tumours [22-25]. We report superior OS of the GC regi-
men with comparable high grade toxicity (grade 4 hae-
matologic and grade 3/4 non-haematologic disease).
Methods
Patient population
This is a retrospective study identifying all patients trea-
ted at the University Hospitals of Erlangen with chemor-
adiotherapy. Patients were identified by reviewing the
tumour board minutes and the departmental minutes of
Radiation Oncology. Patients with locally advanced pan-
creatic carcinoma (LAPC) were selected for primary
CRT at our local tumour board. The following eligibility
criteria were used: Histological proof of ductal adeno-
carcinoma prior to CRT. In general, LAPC was defined
along the lines of the Practice Guidelines in Oncology™
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of the National Comprehensive Cancer Network [26]: A
minimal Karnofsky performance score ≥60% was
required and pretherapeutic laboratory requirements for
chemotherapy were: leukocyte count ≥4000/μL, platelet
count ≥100,000/μL, bilirubin < 2.0 mg/dL, and a creati-
nine clearance ≥60 mL/min. Echocardiography was per-
formed to ensure that prehydration before cisplatin
chemotherapy was tolerable. Jaundiced patients under-
went bile duct stenting prior to therapy. Patients being
treated with either FM or GC chemotherapy were eligi-
ble. These two schedules were used almost exclusively
in our institution. Choice between FM and GC is
explained below.
Treatment
Radiation treatment planning was performed as
described elsewhere in detail [27]. Briefly, 3-D confor-
mal treatment planning was applied based on IV and
oral contrast enhanced planning CT scans. PTV_5040
(planning target volume) comprised the primary
tumour (GTV) and elective lymphatic nodes and
PTV_5580 comprised the GTV with margins only.
Elective nodes treated in pancreatic head and body
tumours were the regions 8, 9, 12, 13, 14, 16a2, 16b1,
17, and 18 to the right of the left edge of the aorta
according to the Japanese Gastric Cancer Associa-
tion [28]. The total PTV_5040 volume was not allowed
to be larger than 800 mL. Conventional fractionation
with single doses of 1.8 Gy was used. The dose con-
straints for the organs at risk were for the liver V30 <
50%, for the ipsilateral kidney V20 < 50% and for the
contralateral kidney V20 < 30%, and Dmax to the spinal
cord < 40 Gy.
For the 5-fluorouracil and Mitomycin C regimen
(FM), 5-FU was given as 24 h continuous infusion of
1000 mg/m2/day on days 1-5 and days 29-33. Mitomy-
cin C was given as an IV bolus injection (10 mg/m2)
on days 1 and 29 (Figure 1). For the gemcitabine/Cis-
platin (GC) regimen, 300 mg/m2 gemcitabine and 30
mg/m2 cisplatin were given intravenously on days 1, 8,
22 and 29 being the first day of radiotherapy in weeks
1, 2, 4 and 5. Gemcitabine was given first followed
immediately by Cisplatin which was given < 1 hour
prior to radiotherapy. Supportive therapy comprised
gastric acid protection during and at least 3 months
after therapy, antiemetic therapy, and nutritional sup-
port which in most patients was given as supportive
parenteral feeding as required. There was a gradual
change in the institution from FM to GC after the
completion of a phase I study on concurrent GC che-
moradiotherapy [29]. After chemoradiotherapy some
patients had additive gemcitabine chemotherapy (1000
mg/kg; d1, 8, 15, q29d) which was given at the discre-
tion of the treating physician.
Efficacy, treatment evaluation and statistical analysis
Follow up examinations were performed six weeks after
the end of treatment and then every 3 months for the
first 2 years after chemoradiotherapy and thereafter
every 6 months for at least 3 years. In addition to physi-
cal examination, laboratory tests (full blood cell counts,
biochemistry including liver and kidney function tests
and CA-19-9), and ultrasound of the abdomen. CT
abdomen and a chest X-ray or a CT abdomen/chest
were performed every 6 months. Statistical data analysis
was done with the software IBM Statistical Package for
the Social Sciences®, version 19.0. Kaplan-Meier plots
were calculated for analysis of survival. Survival was cal-
culated from date of diagnosis to date of death or date
of last contact. Pair wise log-rank test was employed for
comparison of the differences in survival in subgroups
of patients. The RTOG toxicity criteria [30], the LENT-
SOMA criteria [31] (side effects of radiotherapy) and
the CTCAE v3.0 toxicity criteria of the NCI (haematolo-
gical side effects) were used to classify acute and chronic
treatment-related side effects. The treatment was in
accordance with the ethical standards of the local com-
mittee on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2000, and all patients
provided informed consent before therapy.
Results
Patient characteristics
Ninety-three patients from our centre were treated with
either FM or with GC chemoradiotherapy. The median
Figure 1 Schedule of two chemoradiotherapy treatment
schedules (gemcitabine/cisplatin versus 5-fluorouracil/
mitomycin C. Combination of radiotherapy with 5-fluorouracil
and mitomycin C (FM) in the upper panel versus gemcitabine and
cisplatin (GC) in the lower panel. Each arrow in the top panel
corresponds to one daily fraction of radiotherapy. The last three
arrows represent a boost restricted to the tumour (= Planning
target volume, PTV5580) whereas the rest of the fractions included
additionally the regional lymphatics (PTV5040) and this is
illustrated in the right hand Euler diagram. Abbreviations: 5-FU =
5-fluorouracil; Cis = cisplatin; Gem = gemcitabine; Gy = Gray;
MMC = Mitomycin C.
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follow-up time at analysis was 11.7 months. At the time
of analysis 6 patients were alive (6%). The baseline
patient characteristics are summarised in Table 1. The
majority of the patients were diagnosed with cT4
tumours (52%). In both arms, 91% of the patients had
an ECOG performance status of at least 2, respectively.
All patients had ductal adenocarcinoma of the pancreas
as diagnosed by biopsy or laparoscopically during an
attempt of resection. Reasons for non-resectability were
vascular involvement in most patients or nodal disease
as diagnosed on contrast enhanced computed
tomography.
Treatment and outcome
The median duration of radiotherapy was 43 days (SD
4.8 days) in all patients (FM, 43 days, SD 5.2 days; GC,
42 days, SD 4.9 days). In the FM group and in the GC
group the median total doses to the PTV_5040 (primary
and lymphatics) were 50.4 Gy (range 28.8 - 50.8 Gy;
41.4 - 55.8 Gy) and the cumulative doses to the
PTV_5580 (GTV and margin) were 55.8 Gy (28.8 - 57.6
Gy; 41.4 - 59.4 Gy), respectively. Radiotherapy was not
completed in four patients: two patients treated with
FM developed distant metastasis during treatment (total
dose 28.80 and 46.80 Gy), one patient with GC received
a total dose of only 41.40 Gy due to decreasing perfor-
mance status and 1 patient treated with GC could not
be fully treated due to cholangitis after having reached a
total dose of 50.4 Gy.
Median overall survival time for all 93 patients was 11.5
months and 12 month overall survival rate was 48%. At
analysis four patients were alive in the FM group and 2
in the GC group. Median overall survival for patients
treated with FM was 9.7 months and 12.7 months for
patients treated with GC (Figure 2). One-year overall sur-
vival rates were 40% in FM and 53% in GC treated
patients and this difference was statistically significant (p
= 0.009). Survival of 36 patients who had additive che-
motherapy after radiotherapy was not statistically longer
than that of the 57 patients without (p = 0.24). The vast
majority of the patients died from metastatic disease.
There was neither a statistically significant correlation
between the use of additive chemotherapy, the dose
intensity of additive chemotherapy and ECOG perfor-
mance status nor between additive chemotherapy and
the type of chemoradiotherapy (GC vs FM). Patients with
FM and GC had a median of 7 cycles of gemcitabine.





patients % patients %
All patients 35 58
Age Median (Range) 63 (37 - 75) 63 (35 - 76)
Gender Male 23 66 36 62
Female 12 34 22 38
Surgery No resection 26 74 41 71
resection 9 26 15 29
Tumour location Head 25 71 40 69
Head/Body 3 9 5 9
Body 5 14 9 16
Body and tail 1 3 3 5
tail - - 1 2
cT 1997 1 1 3 2 3
2 8 23 8 14
3 8 23 16 28
4 18 51 32 55
cN 1997 0 15 43 27 47
1 20 57 31 53
UICC 1997 I 4 11 7 12
II 3 9 7 12
III 9 26 12 20
IVa 17 49 31 53
IVb 2 6 1 1
Grading 1 3 9 3 5
2 15 43 28 48
3 5 14 16 28
4 0 - 0 -
Abbreviations: R0 = clear resection, R1 = positive margin, RX = resection
margin uncertain.
Figure 2 Kaplan-Meier plot of overall survival of patients.
Concurrent chemoradiotherapy with gemcitabine/cisplatin (green
solid line, n = 58) versus 5-fluorouracil/mitomycin C (blue dotted
line, n = 35). Y-axis = percentage of patients surviving. Median
overall survival time 12.7 vs 9.7 months; 1 year overall survival rate:
53% vs 40%.
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Chemotherapy dose reductions and tolerance results
As for the concurrent chemotherapy with radiotherapy,
GC dose reductions were necessary in 22% of the
patients. A dose reduction of FM was necessary in 14%
of the patients. The main reasons for treatment delay or
dose reduction of simultaneous chemotherapy were leu-
kocytopenia, thromocytopenia or both combined for
both treatment groups.
The acute toxicities during chemoradiotherapy accord-
ing to the NCI-CTC criteria are shown in Table 2. The
GC regimen led to more grade 3 leukocytopenia and
thrombocytopenia than the FM regimen, but not to
more frequent grade 4 myelosuppression. Combined
grade 3/4 leukocytopenia of FM and GC were 37% and
48% respectively. No grade 3 or grade 4 febrile neutro-
penia was observed. Platelets count reduction was the
most relevant grade 4 toxicity for both regimens at 11%
and 12% respectively necessitating platelet prophylactic
transfusions but no acute bleeding episodes were
observed for both chemotherapy schedules. Combined
grade 3/4 thrombocytopenia was 20% vs 36%, respec-
tively in the FM and GC groups. Grade 3 upper gastroin-
testinal (GI) tract toxicity was more frequent with the
FM regimen, again with no obvious difference for grade 4
upper GI toxicity being a rare event. Combined higher
grade (3 or 4) nausea and vomiting were 37% vs 18% in
FM and GC groups respectively. The median body mass
index (BMI) was reduced by 1.0 kg/m2 (standard devia-
tion 0.98 kg/m2, range 0 - 4.4 kg/m2) in the GC group
and 0.9 kg/m2 (standard deviation 1.3 kg/m2, range -5.5 -
2.9 kg/m2) in the FM group at the nadir of the weight.
For the 10 patients with a BMI < 20 kg/m2 the median
weight loss was 0.8 kg/m2 (standard deviation 0.5 kg/m2,
range 0 - 1.8 kg/m2). We also analysed long-term toxicity:
although no patients had hepatotoxicity or renal toxicity
during follow up, one patient in the GC group had a duo-
denal bleeding from an ulcer four months after the end
of therapy which was fatal. Proton pump inhibitor treat-
ment had been discontinued after treatment despite of
being prescribed in the end-of-treatment letter.
Discussion
Currently it is not clear which type of concurrent
chemotherapy is best when combined with radiotherapy.
While the standard of care for CRT is to combine a
fluoropyrimidine with radiotherapy (5-fluorouracil or
more recently also capecitabine) [10], there is a
tendency to use more and more gemcitabine based che-
moradiotherapy. The combination of 5-FU and mitomy-
cin C that we have used in this report was previously
employed for CRT in a number of trials in PDAC
[22,23,32-34]. Mitomycin C was hypothesised to be use-
ful in addition to 5-fluorouracil because of its predomi-
nant effectiveness in hypoxic conditions [35] since
severe hypoxia was shown to be present in pancreatic
tumours [36]. However, after the publication of a rando-
mised phase III trial by Burris et al. [11] showing the
superiority of gemcitabine compared with fluorouracil
for the treatment of patients with advanced pancreatic
cancer, much effort has been made to combine gemcita-
bine-based regimens concurrently with radiotherapy.
This is reflected by the fact that during the last decade a
Table 2 Acute toxicity of chemoradiotherapy according to CTC-NCI criteria
Toxicity 5-FU, Mitomycin C n = 35 Gemcitabine, Cisplatin n = 58
CTC-Grade % %
Leukocytes 2 9 26 23 40
3 11 31 26 45
4 2 6 2 3
Platelets 2 4 11 13 22
3 3 9 14 24
4 4 11 7 12
Haemoglobin 2 5 14 31 53
3 3 9 2 3
4 0 - 0 -
Nausea 2 11 31 23 40
3 7 20 5 9
4 0 - 1 2
Vomiting 2 7 20 19 33
3 5 14 3 5
4 1 3 1 2
Diarrhoea 2 2 6 4 7
3 0 - 1 2
4 0 - 0 -
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total number of 36 clinical trials using gemcitabine and
chemoradiotherapy have been published in PubMed, the
majority of them after 2005. The combination of gemci-
tabine and cisplatin concurrently with radiotherapy
which we have used in this analysis was also tested in a
number of CRT trials [37-40] and chemotherapy trials
[41]. Preclinical studies have suggested a synergistic
interaction between gemcitabine cisplatin being the
result of gemcitabine incorporation into DNA and an
increase of platinum -DNA adduct formation [16,17].
Therefore, this study reports the use of two chemothera-
peutic regimens based on biological hypotheses.
One of the strengths of this retrospective comparison
is the homogeneity of the treatment variables and of the
selection process of the patients for definitive chemora-
diotherapy within one single centre in a large number of
patients. Both, median overall survival time (12.7 versus
9.7 months) and 12-month overall survival rate (53%
versus 40%) were statistically significantly longer in the
patient cohort treated with the GC regimen compared
to the FM regimen. Comparing our survival results with
other trials which have investigated the use of 5-fluor-
ouracil versus gemcitabine chemoradiotherapy, Crane et
al. showed a trend favouring gemcitabine (53 vs 61
patients) based CRT [42] and Li et al. reported a statisti-
cally significant survival advantage for patients treated
with gemcitabine concurrently to radiotherapy over
those treated with 5-fluorouracil (16 vs 18 patients) [43].
In contrast, no advantage of gemcitabine over 5-fluor-
ouracil CRT was detected in two other trials. However,
the trial reported by Brasuniene et al. was very small (10
vs 9 patients per arm) and therefore was substantially
underpowered to be able to detect any difference [44].
The second negative trial, reported by Wilkowski et al.
[37] compared 3 arms, 5-fluorouracil (30 patients), GC
(31 patients) and GC chemoradiotherapy followed by
GC chemotherapy (27 patients). As this trial is the only
one using the GC combination as the here reported
trial, it is worth to compare the two trials in more
detail. The median overall survival rate for the GC arm
and the arm with GC CRT followed by GC chemother-
apy was 9.3 and 7.3 months, respectively in this study
whereas we observed a median overall survival rate of
12.7 months. A hypothetical explanation for this differ-
ence is a higher total radiation dose to the primary
tumour in our trial (55.8 Gy versus 50 Gy). The patient
characteristics between the two studies were similar.
However, it needs to be stressed that our analysis is ret-
rospective in nature and therefore we cannot exclude
factors such as selection bias or other inhomogeneities.
We have tested known factors influencing survival as
good as possible and these included TNM staging and
performance status and did not observe any significant
differences. Just very recently a meta-analysis on the use
of gemcitabine based chemoradiotherapy compared to
5-FU including 229 patients from randomised controlled
trials was published [25]. This analysis described a survi-
val advantage of gemcitabine based chemoradiotherapy
compared to 5-Fu based for 12 month overall survival
rates (RR 1.54, 95% CI 1.05 - 2.26, p = 0.03).
The toxicity analysis of the two regimens showed
that the GC regimen led to a higher number of haema-
tologic grade 3 toxicities, but interestingly not of grade
4 toxicities. Nausea and vomiting were the most fre-
quent higher grade non-haematologic toxicities in both
groups. Surprisingly, grade 3 nausea and vomiting were
more frequent in the FM regimen despite of the eme-
togenic effect of cisplatin in the GC regimen. This
might be attributable to the fact that antiemetic ther-
apy has improved over time and FM being chronologi-
cally the first regimen used in this cohort. Comparing
haematologic toxicity of the GC regimen in our trial
with that reported by Wilkowski combined grade 3/4
leukocytopenia was comparable (48% versus 52%),
grade 3/4 thrombocytopenia was less frequent in our
trial (36% versus 52%) and grade 3/4 nausea was com-
parable (11% versus 13%). The addition of mitomycin
C to 5-fluorouracil in our trial led to significant differ-
ences in haematologic grade 3/4 toxicity when compar-
ing it with the Munich trial (thrombocytopenia: 20%
versus 4%; leukocytopenia: 37% versus 4%) and nausea
(20% vs 0%). The comparison of our study with the
FFCD-SFRO [9] and with the ECOG [6] trials shows
that our GC protocol resulted in lower GI toxicity
compared to the ECOG regimen but more neutropenia
which we attributed to the addition of cisplatin to
gemcitabine. Compared with the FFCD trial our FM
regimen led to a lower rate of non-haematological
toxicity but a higher rate of thrombocytopenia which
we attributed to the use of mitomycin C. The above
mentioned recently published meta-analysis found sig-
nificant differences of leukocytopenia, thrombocytope-
nia and gastrointestinal bleeding being more frequent
in the gemcitabine group [25]. This might be due to
suboptimal radiation techniques used in the trials with
the majority of the patients being treated about a dec-
ade ago. At that time the toxicity-volume relationship
of gemcitabine chemoradiotherapy was not yet
described as well as now and IMRT was not yet as
commonly used as it is now.
Conclusions
Summarising our results in terms of efficacy and toler-
ance this retrospective report with its inherent limita-
tions does not support the use of the FM regimen. Not
only was it more toxic for grade 3 upper GI toxicity
which is especially stressful for the patient but also less
efficient and this is in line with a recent negative trial
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comparing chemoradiotherapy with radiotherapy only
using this regimen [23]. On the other hand, the GC
regimen was superior to FM in overall survival and rea-
sonably well tolerated. However, tight upper limits of
absolute treatment volumes have repeatedly described to
be of high importance for the tolerance of gemcitabine
based chemoradiotherapy regimens and we therefore
advocate for very strict target volume definitions [27,45].
Last but not least it should be mentioned that currently
the SCALOP trial in the UK compares gemcitabine vs.
capecitabine based chemoradiotherapy in a randomised
controlled phase II trial from which we expect will allow
to draw firmer conclusions in the near future.
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